Literature DB >> 6456897

Cefoperazone in lower respiratory tract infections.

C J Woods, R B Ellis-Pegler.   

Abstract

17 hospitalised patients with a wide variety of common lower respiratory tract infections received at least 6 days of intravenous bolus cefoperazone 1.0g 12-hourly. Disease was caused by Haemophilus influenzae, Streptococcus pneumoniae, Staphylococcus aureus, and mixed anaerobes in 1 patient. All isolates were sensitive to cefoperazone. 11 patients were cured, 4 improved, and 2 failed (1 of whom had an anaerobic empyema). Toxicity and side effects were infrequent. In general cefoperazone was effective therapy for these infections.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6456897     DOI: 10.2165/00003495-198100221-00020

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  5 in total

1.  Microbiological studies on cefoperazone.

Authors:  F H Kayser
Journal:  Clin Ther       Date:  1980       Impact factor: 3.393

2.  Clinical trials with cefoperazone in the field of internal medicine in Japan.

Authors:  K Mashimo; O Kunii
Journal:  Clin Ther       Date:  1980       Impact factor: 3.393

3.  Single-dose pharmacokinetics of cefoperazone following intravenous administration.

Authors:  W A Craig
Journal:  Clin Ther       Date:  1980       Impact factor: 3.393

4.  Comparative activity and beta-lactamase stability of cefoperazone, a piperazine cephalosporin.

Authors:  H C Neu; K P Fu; N Aswapokee; P Aswapokee; K Kung
Journal:  Antimicrob Agents Chemother       Date:  1979-08       Impact factor: 5.191

5.  Susceptibility of anaerobic bacteria to cefoperazone and other beta-lactam antibiotics.

Authors:  N V Jacobus; F P Tally; M Barza; S L Gorbach
Journal:  Clin Ther       Date:  1980       Impact factor: 3.393

  5 in total
  1 in total

Review 1.  Cefoperazone: A review of its in vitro antimicrobial activity, pharmacological properties and therapeutic efficacy.

Authors:  R N Brogden; A Carmine; R C Heel; P A Morley; T M Speight; G S Avery
Journal:  Drugs       Date:  1981-12       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.